So-Young Intl Stock Price, News & Analysis

So-Young International Inc. (NASDAQ: SY), China's leading aesthetic treatment platform, reported Q2 2025 financial results with total revenues of RMB378.7 million (US$52.9 million), down 7.0% year-over-year. The company's aesthetic treatment services revenue surged 426.1% to RMB144.4 million, becoming the largest revenue contributor for the first time.

The company now operates 29 branded aesthetic centers across 9 major Chinese cities, with 25 centers achieving positive monthly operating cash flow. Key operational metrics showed significant growth, with verified treatment visits reaching 67,400 and active users exceeding 100,400. However, So-Young reported a net loss of RMB36.0 million, compared to a net income of RMB18.9 million in Q2 2024.

For Q3 2025, So-Young expects aesthetic treatment services revenues between RMB150.0-170.0 million, representing 230.5-274.6% year-over-year growth.

[ "Aesthetic treatment services revenue grew 426.1% year-over-year to RMB144.4 million", "25 out of 29 branded aesthetic centers achieved positive monthly operating cash flow", "Verified treatment visits increased significantly to 67,400 from 14,000 year-over-year", "Active users grew to 100,400 from 16,000 in the corresponding period", "Strong Q3 2025 guidance projecting 230.5-274.6% growth in aesthetic treatment services" ]

So-Young International (NASDAQ: SY), China's leading aesthetic treatment platform, will release its Q2 2025 financial results on August 15, 2025, before U.S. markets open.

The company will host an earnings conference call on August 15, 2025, at 7:30 AM ET (7:30 PM Beijing/Hong Kong Time). A telephone replay will be available until August 22, 2025, and investors can also access the live and archived webcast through the company's investor relations website.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq on July 2, 2025, after maintaining a closing bid price of $1.00 or higher for its American depositary shares (ADSs) for 10 consecutive business days from June 17 to July 1, 2025.

This development resolves the compliance issue that began on August 28, 2024, when So-Young was initially notified of non-compliance. The company had received two compliance periods: an initial 180-day period until February 24, 2025, followed by an extension until August 25, 2025. With this requirement now met, Nasdaq has closed the matter.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, announced an extension to its planned ADS ratio change implementation. The company previously intended to modify its ADS to Class A ordinary shares ratio from 13:10 to 1:15, effectively implementing a reverse ADS split, scheduled for June 30, 2025. However, So-Young has decided to postpone the change to allow additional time for preparation. The ratio change will automatically process through the depositary bank, with existing ADSs being cancelled and new ones issued. Fractional new ADSs will be sold, with net proceeds distributed to holders. While the stock price is expected to increase proportionally post-change, the company provides no guarantees regarding the final price adjustment.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, announced plans to modify its ADS ratio from 13 ADSs per 10 Class A ordinary shares to 1 ADS per 15 Class A ordinary shares. This change, effective June 30, 2025, will function similarly to a reverse ADS split. The company's Class A ordinary shares remain unaffected, and SY will continue trading on Nasdaq under the same symbol. The transition will occur automatically, with existing ADSs being cancelled and new ones issued. Fractional ADSs will be aggregated, sold, and proceeds distributed to holders. While the ADS price is expected to increase proportionally, the company provides no guarantees regarding post-change pricing.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, reported Q1 2025 financial results. Total revenues decreased 6.6% to RMB297.3 million (US$41.0 million) compared to Q1 2024. The company reported a net loss of RMB33.1 million (US$4.6 million), wider than the RMB21.2 million loss in Q1 2024. Notable operational highlights include: aesthetic treatment transactions of RMB303.2 million, over 45,500 verified paid visits, and 92,900 verified aesthetic treatments. The company operates 23 aesthetic centers across nine major Chinese cities, with 18 centers achieving positive monthly operating cash flow. Their aesthetic treatment services revenue saw significant growth, increasing 551.4% to RMB98.8 million. For Q2 2025, So-Young expects aesthetic treatment services revenues between RMB120.0-140.0 million, representing 337.3-410.1% YoY growth.

So-Young International Inc. (NASDAQ: SY), China's leading aesthetic treatment platform, has scheduled its first quarter 2025 financial results announcement for May 16, 2025, before U.S. markets open. The company will host an earnings conference call on the same day at 7:30 AM U.S. Eastern Time (7:30 PM Beijing/Hong Kong Time). A telephone replay will be available until March 23, 2025, and interested parties can also access a live and archived webcast of the conference call through the company's investor relations website.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, has announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2024. The report was submitted to the Securities and Exchange Commission on April 18, 2025.

The annual report is accessible through the company's investor relations website at ir.soyoung.com. Shareholders and ADS holders can request a complimentary hard copy of the annual report, which includes audited consolidated financial statements, by emailing ir@soyoung.com.

So-Young International (Nasdaq: SY), China's leading aesthetic treatment platform, announced that its CEO and chairman Mr. Xing Jin, through Beauty & Health Holdings , has purchased 4,544,820 American depositary shares (ADSs) representing 3,496,015.38 Class A ordinary shares in the open market on March 31, 2025.

The purchase was made at US$0.90 per ADS, totaling US$4,090,338, using personal funds. This transaction increased Jin's beneficial ownership to 24.9% of the company's outstanding shares. The purchase was executed in accordance with Rule 10b-18 of the Securities Exchange Act of 1934.

The company's directors stated that the share purchase is not expected to materially impact So-Young's financial position or business operations. Jin expressed that this purchase reflects his continued confidence in the company's long-term growth prospects.